Form 8-K

8-K — BullFrog AI Holdings, Inc.

Accession: 0001493152-26-013684

Filed: 2026-03-30

Period: 2026-03-27

CIK: 0001829247

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001829247

2026-03-27

0001829247

BFRG:CommonStockParValue0.00001Member

2026-03-27

0001829247

BFRG:TradeableWarrantsMember

2026-03-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 27, 2026

BULLFROG

AI HOLDINGS, INC.

(Exact

name of Registrant as specified in its charter)

Nevada

001-41600

84-4786155

(State

or other jurisdiction of incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

325

Ellington Blvd, Unit 317

Gaithersburg,

MD 20878

(Address

of principal executive offices) (Zip Code)

Registrant’s

telephone number, including area code: (240) 658-6710

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.00001

per

BFRG

The

Nasdaq Stock Market LLC

(The

Nasdaq Capital Market)

Tradeable

Warrants

BFRGW

The

Nasdaq Stock Market LLC

(The

Nasdaq Capital Market)

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01. Entry Into a Material Definitive Agreement.

March 27, 2026, BullFrog AI Holdings, Inc. (the “Company”) entered into a Feasibility Agreement (the “Agreement”)

with a global pharmaceutical company (the “Client”). Pursuant to the Agreement, the Company will apply its proprietary methodology

and artificial intelligence and machine learning tool, bfLEAP®, to discover and provide the Client with prioritized

drug target candidates, associated causal gene networks with target near-neighbors unblinded, and target dossiers for advancement-ready

drug candidates for major depressive disorder (MDD). The Agreement will remain in full force and effect for one year from the

execution of the Agreement.

connection with the Agreement, the Company is eligible to receive pre-determined milestone payments upon the delivery of certain deliverables

to the Client. The Client will have the option to receive the exclusive right to use a selected “final target” drug candidate

for its research and development purposes for a period of three years.

The

Client may terminate the Agreement without cause upon thirty days’ notice to the Company, and either party may terminate the Agreement

immediately on written notice of a breach of the Agreement that remains uncured for thirty days following receipt of notice of such breach

from the non-breaching party.

The

Agreement also contains customary representations, warranties and covenants, including with respect to intellectual property, as well

as provisions relating to indemnification, confidentiality and other matters.

The

foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the redacted

text of the Agreement, a copy of which is filed (with certain portions redacted in accordance with Item 601(b)(10)(iv) of Regulation

S-K) as Exhibit 10.1 hereto and incorporated by reference herein.

Item

8.01. Other Matters.

March 30, 2026, the Company issued a press release announcing the entry into the Agreement. A copy of the press release is attached

hereto and incorporated herein by reference as Exhibit 99.1.

Item

9.01. Financial Statements and Exhibits.

(d) Exhibits.

The

following exhibits are being furnished herein:

Exhibit

No.

Description

10.1*#

Feasibility

Agreement, dated as of March 27, 2026, by and between BullFrog AI Holdings, Inc. and Client.

99.1

Press release, dated March 30, 2026.

104

Cover

Page Interactive Data File (formatted as Inline XBRL)

Portions of this exhibit have been redacted in accordance with Regulation S-K Item 601(b)(10)(iv). The Company agrees to furnish

supplementally an unredacted copy of the exhibit to the SEC upon its request.

Schedules and certain exhibits have been omitted pursuant to Regulation S-K Item 601(b)(2). The Company agrees to furnish

supplementally any omitted schedules and exhibits to the SEC upon its request.

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

March 30, 2026

BullFrog AI Holdings, Inc.

By:

/s/

Vininder Singh

Name:

Vininder

Singh

Title:

Chief

Executive Officer

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit 10.1

CERTAIN

INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

THE OMITTED PORTIONS OF THIS DOCUMENT ARE INDICATED BY [***].

FEASIBILITY

AGREEMENT

[***]

and its affiliates (“[***]”) desire to retain BullFrog AI Holdings, Inc. (“Company”), with an address

of 325 Ellington Blvd. #317 Gaithersburg, Md 20878, for performance of Feasibility Services (as defined below) pursuant to the terms

and conditions of this Feasibility Agreement (“Agreement”).

1. Feasibility

Services. Company shall perform the activities detailed in the description of services

attached hereto as Exhibit A (Description of Feasibility Services), which may be amended

in writing by the parties at any time (the “Feasibility Services”).

2. Company

Obligations; Contacts.

(a) Company

represents and warrants that each individual performing Feasibility Services hereunder is

an employee, consultant, or approved subcontractor of Company. Company (i) shall cause each

such employee, consultant or approved subcontractor performing under this Agreement to abide

by the applicable terms and conditions hereunder, and (ii) will be liable for the acts and

omissions of such employees, consultants, or approved subcontractor.

(b) Company

shall perform the Feasibility Services consistent with the state of current data quality

and integrity research principles, AI/ML best practices, and shall observe safe and diligent

handling procedures of Deliverables.

contact(s) with [***] is [***], email [***].com, or whomever [***] may designate in writing.

[***]’s contact(s) with Company is Vin Singh[***] or whomever Company may designate in writing.

3. Reports,

Deliverables.

(a) As

[***] may request, and as may be set forth in Exhibit A (Description of Feasibility

Services), Company shall keep [***] regularly advised on the progress of the Feasibility

Services in a format that is mutually agreed upon between the parties (collectively “Progress

Reports”).

(b) Company

shall deliver to [***] (i) Feasibility assessment of Dentate Gyrus for MDD samples as defined

in the Exhibit A; (ii) list of targets prioritized by Company (“Target List”),

(iii) unblinded networks with tractability assessments for [***] Preselected Targets (“Target

Network”), and Final Target with associated Target Network (collectively “Deliverables”

described in detail in Exhibit A) according to the process and details set forth in Section

10(c).

4. Compensation.

(a) In

consideration for Company’s performance of the Feasibility Services described in this

Agreement, [***] shall pay Company an amount not to exceed the amount set forth in Exhibit

A (Description of Feasibility Services). [***] shall pay Company within ninety (90) days

of [***]’s receipt and approval of an invoice. Unless otherwise set forth in Exhibit

A, all invoices must be submitted by Company within forty-five (45) days of performance

of the related Feasibility Services hereunder. In the event of termination of this Agreement

by [***] without cause, [***] shall pay Company for Feasibility Services performed and, as

applicable, expenses incurred through the date of termination in accordance with the budgeted

amounts set forth in Exhibit A and invoice approval terms of this Section 4.

(b) Company

understands that the terms and conditions of this Agreement, including, but not limited to,

the name or other information of Company and Company’s employees performing the Feasibility

Services, and the amount of any payment made hereunder, may be disclosed and made public

by [***] as required by law or regulation, industry code, or as agreed by the parties, including

those disclosures of transfers of value as between [***] and Company required for the purposes

of relevant transparency rules. Company hereby consents to the collection, processing, and

disclosure of Company’s employees’ personally identifiable information to the

extent required under any such law, regulation, or code. For the purposes of collection,

processing and disclosure, [***] may transfer such information outside the United States

and European Union. As reasonably requested by [***], Company agrees to cooperate in good

faith with [***] to promptly provide accurate and complete information in connection with

payments made to or by the Company in relation to this Agreement.

final payment to be made under this Agreement may be accompanied by a financial reconciliation,

taking into account the payment to be made in accordance with this Section 4 and,

only after the performance of all Feasibility Services contemplated hereunder, the delivery

to [***] of all Reports described in Section 3 (Reports, Deliverables) of this Agreement

and the return of all items described in Section 8 (Confidential Information) of this

Agreement. If, at the time of such financial reconciliation, the total amount [***] has paid

is less than the amount to which Company is entitled hereunder, [***] shall pay the amount

due Company at such time. Any overpayment due [***] pursuant to this Agreement, as determined

at the time of final reconciliation, will be made payable to [***], within forty-five (45)

days of [***]’s notice to Company of such overpayment and sent to: [***], along with

an explanation for such payment and accompanying support documentation for the remittance

with a copy to the [***] contact set forth in Section 2 (Company Obligations; Contacts)

of this Agreement.

Feasibility Services Agreement CONFIDENTIAL 1

(d) Company

shall maintain, at no additional charge to [***], in accordance with generally accepted accounting

principles, complete and accurate records related to: (i) amounts billed to and payments

made by [***] hereunder and (ii) expenses incurred on behalf of and reimbursed by [***] hereunder.

Company shall provide [***] supporting documentation concerning any disputed invoice or payment

within thirty (30) days after [***] advises Company of a dispute. Payments made hereunder

will be subject to final adjustment as determined by such review. Company shall retain such

records for a period of three (3) years from the termination or expiration of this Agreement

or the length of time as may be required by any federal, state or local law, ordinance or

regulation, whichever period is longer.

(e) Company

acknowledges and agrees that [***] is providing compensation under this Agreement based on

Company’s particular skills and experience and is not offering Company this fee on

the grounds of any official or governmental position Company may hold.

(f) When

required by any applicable law or regulation, [***] will deduct withholding tax from any

amounts otherwise due Company under this Agreement and remit such amounts to any relevant

tax authority. Any such amounts deducted by [***] shall be treated as having been paid by

[***] to Company for purposes of this Agreement. Company and [***] shall cooperate in good

faith to qualify any amounts due Company under this Agreement for any applicable reductions

of, or exemptions from, withholding tax under any applicable law or regulation.

5. Electronic

Data. If performance of the Feasibility Services under this Agreement involves the recording

or transmittal to [***] of electronic data, Company shall comply with the electronic data

obligations set forth in Exhibit B attached hereto, as applicable, as well as any

restrictions or obligations arising under applicable data protection laws. Company shall

maintain reasonable administrative, technical, and physical safeguards and other security

measures commensurate, as applicable, with the types of confidential information being processed,

created, stored, transmitted, or archived by Company for or on behalf of [***].

6. Term

and Termination.

(a) This

Agreement will be effective upon full execution by the parties (“Effective Date”)

and will be effective for a period of one (1) year thereafter (“Term”).

(b) [***]

may terminate this Agreement without cause upon thirty (30) days’ notice to Company.

If [***] is paying compensation to Company in relation to the Feasibility Services, in the

event of [***]’s termination of this Agreement without cause, [***] will compensate

Company for (i) all Feasibility Services actually performed in accordance with the terms

of this Agreement, and (ii) all reasonable non-cancellable expenses actually incurred by

Company in relation to the Feasibility Services. Notwithstanding the above, for no reason

will [***] be obligated to pay Company an amount in excess of the “Total Compensation

(not to exceed)” amount set forth in Exhibit A.

party may terminate this Agreement immediately upon written notice to the other party in

the event of a material breach by the other party of any provision of this Agreement that

remains uncured thirty (30) days following receipt of notice of such breach from the non-breaching

party. Termination or expiration of this Agreement will not affect any rights or obligations

which have accrued prior to termination thereof, or any other rights or remedies provided

at law or equity which either party may otherwise have.

7. Acceptance

Procedures; Failure to Perform. [***] acknowledges and agrees that, in the performance

of the Feasibility Services, Company shall be required to perform the Feasibility Services

in accordance with this Agreement and applicable professional and scientific standards, but

that Company cannot guarantee a particular outcome. Company is responsible for the quality,

technical accuracy and completeness of Feasibility Services and Deliverables furnished to

[***].

Feasibility Services Agreement CONFIDENTIAL 2

8. Confidential

Information.

(a) At

all times during the Term and for a period of ten (10) years following termination or expiration

of this Agreement in its entirety, Company shall, and shall cause its officers, directors,

employees and agents to, keep confidential and not publish or otherwise disclose to a third

party and not use, directly or indirectly, for any purpose, any Confidential Information

furnished or otherwise made known to it, directly or indirectly, by [***], except to the

extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential

Information” means all information or data provided orally, visually, in writing or

other form by or on behalf [***] (or an Affiliate or representative of [***]) to Company

(or to an Affiliate or representative of Company) in connection with this Agreement, including

the list of Preselected Targets, the identity of [***]’s choice of the Final

Target, and, the scientific, regulatory or business affairs or other activities of [***],

or except any portion thereof which:

(i) has

been published by a third party or otherwise is or hereafter becomes part of the public domain

by public use, publication, general knowledge or the like through no wrongful act, fault,

or negligence on the part of Company;

(ii) has

been in Company’s prior to disclosure by [***] without any obligation of confidentiality

with respect to such information; or

(iii) is

subsequently received by Company from a third party without restriction and without breach

of any agreement between such third party and [***];

(iv) in

each of (i), (ii) and (iii), as shown by Company’s written records.

(b) Upon

the earlier of completion of the Feasibility Services or termination, Company shall return

to [***] or destroy all Confidential Information as directed by [***]. Notwithstanding anything

contained in Section 19 (Dispute Resolution) of this Agreement, the parties hereto

agree that in the event of Company’s breach of this Section 11, [***] will be

entitled to seek injunctive relief from any court of competent jurisdiction, without proof

of damages, in addition to any other remedies that may be available at law or equity to [***].

in the reasonable opinion of Company’s counsel, any Confidential Information is required

to be disclosed pursuant to law, regulation or court order, Company shall give [***] prompt,

written notice (and in any case at least five (5) days’ notice) in order to allow [***]

to take whatever action it deems necessary to protect its Confidential Information. In the

event that no protective order or other remedy is obtained, or [***] waives compliance with

the terms of this Section 8, Company shall furnish only that portion of the Confidential

Information which Company is advised by counsel as being legally required and shall notify

[***] in writing of the Confidential Information disclosed.

(d) Company

shall not disclose to [***] any information which is confidential or proprietary to a third

party without first obtaining the written consent of both such third party and [***].

(e) Company

Confidential Information: Information disclosed or generated by Company under this Agreement

will be subject to the Bilateral Confidential Disclosure Agreement entered into by the partes

and dated on or about October 21, 2025 (the “NDA”), in addition to the

supplemental confidentiality provisions of this Agreement. Company Pre-existing Intellectual

Property is Confidential Information of Company under the NDA. Subject to the provisions

of Sections 10(c) and 10(d), the Target Network, the Preselected Targets, the Final Target

and the Target Networks are Confidential Information of Company.

9. Data

Privacy and Protection. Company shall comply with the provisions set forth in Exhibit

D (Data Privacy and Protection). Company’s obligations under Exhibit D (Data

Privacy and Protection) shall survive termination or expiration of this Agreement.

10. Ownership;

Intellectual Property; Inventions; Review Period and Targets.

(a) Pre-Existing

Intellectual Property. It is recognized and understood that certain pre-existing inventions

and technologies owned prior to execution of this Agreement or developed independently of

the Feasibility Services are the separate property of [***] or Company and are not affected

by this Agreement. Neither party shall have any claims to or rights in such separate inventions

and technologies of the other party. Such pre-existing inventions and technologies owned

or independently developed by Company shall be “Company Pre-existing Intellectual

Property.”.

(b) Inventions.

“Inventions” shall mean any information, inventions, innovations, ideas,

discoveries or products (whether or not copyrightable or patentable), suggestions, communications,

correspondence, notes, Reports, all data, records, evaluations, or work products which are

conceived, derived, reduced to practice, made or developed by a party as a result of conducting

the Feasibility Services. Inventorship of Inventions shall be determined according to U.S.

patent laws. During the performance of Feasibility Services, Company will develop Target

List and Target Network, which will collectively remain Company Inventions.

Period. Company will share the Target List with [***]. [***] shall have ninety (90) days

after disclosure of the Target List (“Review Period”) to review the available

information and nominate 10 targets (“Preselected Targets”) for access to the

Target Network associated with those targets. Company agrees not to share or disclose Preselected

Targets with any third party until expiration of the Review Period (subject to Section 10.(d)

below). Upon conclusion of the Review Period, [***] may nominate the target for further development

(“Final Target”). The selection and names of Preselected Targets will be [***]

Confidential Information.

(d) Target

Exclusivity Term . In the event [***] choses one (1) Final Target and pay Company a one-time

“Target Exclusivity Fee”, Company hereby agrees not to disclose the Final Target

and its Target Network to any third party for the duration of three (3) years (“Target

Exclusivity Term”). During Target Exclusivity Term, [***] shall have the right to use

Final Target for any business purposes, except [***] will not sell the Final Target and Associate

Network to any third party during that time.

Feasibility Services Agreement CONFIDENTIAL 3

11. Presentations

and Publications. Company shall not present or publish, or submit for publication, any

work resulting from the Feasibility Services that references or relates to [***]’s

Confidential Information.

12. Publicity.

Company shall not disclose the existence or terms of this Agreement or use [***]’s

name, trademarks, trade names, servicemarks or logos in any publicity, advertising, or announcement,

without [***]’s prior written consent, except, subject to section 8.(c), as required

by law including U.S. securities laws.

13. Representations,

Warranties and Covenants.

(a) Each

party represents and warrants that: neither this Agreement nor any payment hereunder is in

exchange for any explicit or implicit agreement or understanding that Company purchase, lease,

order, prescribe, recommend or otherwise arrange for, or provide formulary or other preferential

or qualifying status for the use of [***] products; and the total payment for the Feasibility

Services under this Agreement represents the fair market value for the Feasibility Services

and has not been determined in any manner that takes into account the volume or value of

any referrals or business between Company and [***].

(b) Company

represents, warrants, and covenants that:

(i)

in performance of Company’s obligations under this Agreement, Company does and will comply with all applicable existing and future

federal, state and local laws, regulations, ordinances and guidance documents, including, but not limited to laws, regulations and guidelines

and other rules related to anti-bribery and anti-corruption, privacy and data protection, tax, immigration and healthcare programs;

(ii)

Company has or shall obtain, and shall keep effective any licenses, certifications, permits or registrations necessary for Company to

provide the Feasibility Services and Deliverables.

(iii)

Company does and will comply with all requirements regarding reporting and management of conflicts of interest and performance of Feasibility

Services does not represent a conflict of interest;

(iv)

Company is not and will not become a party to any contract with any third party which prohibits Company from performing its obligations

under this Agreement or limits Company’s ability to fulfill the terms of this Agreement;

(viii)

the Feasibility Services and any Deliverables provided under this Agreement will be conducted and produced in accordance with relevant

scientific and professional standards and will be free from any security interest or other lien or similar encumbrance;

as expressly set forth in this Agreement, the Feasibility Services and the Deliverables are

provided “as is” and Company disclaims all other warranties, express or implied.

14. Debarment

and Exclusion. Company represents, warrants and covenants that it is not, and will not

engage, directly or indirectly, any person to perform Feasibility Services under this Agreement

if that person has ever been, is currently, or, to the best of Company’s knowledge,

is the subject of a proceeding that could lead to that person becoming, as applicable, (a)

debarred by the FDA under 21 U.S.C. § 335a; (b) excluded, debarred, suspended, or otherwise

ineligible to participate in the Federal health care programs or in Federal procurement or

non-procurement programs; (c) listed on the FDA’s Disqualified and Restricted Lists

for clinical investigators; or (d) convicted of a criminal offense that falls within the

scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended,

or otherwise declared ineligible. In the event that Company receives notice of, or otherwise

becomes aware of, the debarment, proposed debarment or such other exclusion, suspension,

restriction or sanction of itself or any person providing Feasibility Services in connection

with the performance of this Agreement, Company shall notify [***] immediately and [***]

shall have the right to immediately terminate this Agreement.

15. Independent

Contractor. The relationship of the parties under this Agreement is that of independent

contractors. Nothing contained in this Agreement is intended or is to be construed so as

to constitute the parties as partners, joint venturers, or one party as an agent or employee

of the other party. Neither party has any express or implied right under this Agreement to

assume or create any obligation on behalf of or in the name of the other party or to bind

the other party to any contract, agreement or undertaking with any third party, and no conduct

of a party will be deemed to imply such right. To the extent Company engages the services

of any individual to support the Feasibility Services under this Agreement, Company is responsible

for compliance with any applicable employment or tax laws.

Feasibility Services Agreement CONFIDENTIAL 4

16. Assignment.

Neither party shall assign this Agreement nor any part thereof, without the prior written

consent of the other party; provided, however, [***] may assign this Agreement to one of

its subsidiaries or parent entities without such consent; and additionally, [***]

may assign this Agreement to one of its affiliate entities or to a successor in interest

to all or substantially all of its assets to which this Agreement relates, without such consent.

Any attempted assignment in breach of this section will be null and void. Any permitted assignee

shall assume all obligations of its assignor under this Agreement. No assignment shall relieve

any party of responsibility for the performance of any accrued obligation, which such party

then has hereunder.

17. Notices.

Any notices required or permitted under this Agreement must be in writing and refer specifically

to this Agreement, and must be sent by recognized national or international overnight courier,

confirmed facsimile transmission (provided that duplicative copy is provided via confirmed

electronic mail, registered mail or certified mail), confirmed electronic mail, or registered

or certified mail, postage prepaid, return receipt requested, or delivered by hand to the

address as set forth herein. Notices under this Agreement will be deemed to be duly given:

(a) when delivered by hand; (b) upon confirmed electronic mail transmission; (c) two days

after deposit with a recognized national or international courier; or (d) on the delivery

date indicated in the return receipt for registered or certified mail. A party may change

its contact information immediately upon written notice to the other party in the manner

provided in this Section 17.

to Company:

Phone:

[***]

Fax:

[***]

Email:

[***]

to [***]:

with

a copy to:

[***]

18. Indemnification.

Company agrees to indemnify, and hold [***] and its affiliates, employees, directors, officers

and agents harmless against any liability, judgment, demand, action, suit, loss, damage,

cost and other expense (including, but not limited to, reasonable attorneys’ fees to

consider, advise and defend, and court costs) arising from and against any third party suit

or claim made or proceedings brought against [***] arising directly or indirectly out of

(a) Company’s or its employees’ or agents’ gross negligence, recklessness

or willful misconduct, (b) breach by Company of any term of this Agreement including but

not limited to, the representations and warranties set forth in this Agreement; (c) an assertion

or allegation that the Deliverables constitute an infringement of any patent, copyright,

trademark, trade dress, or any other intellectual property right; or (d) injury to a person

(including death) or damage to property caused by Company, its employees or agents.

19. Dispute

Resolution. If a dispute arises between the parties, the parties shall follow the provisions

provided for in the Alternative Dispute Resolution attached hereto as Exhibit C.

20. Survival.

Termination or expiration of this Agreement for any reason will not affect any rights or

obligations which have accrued prior thereto, nor any such rights or obligations which are

meant to survive termination of the Agreement.

21. Severability.

If any provision, right or remedy provided for herein is held to be unenforceable or inoperative

by a court of competent jurisdiction, the validity and enforceability of the remaining provisions

will not be affected thereby.

22. Waiver.

No waiver may be implied from conduct or failure to enforce rights. No provisions of this

Agreement will be deemed waived by [***] unless such waiver is in writing and signed by the

authorized representative of [***]. Waiver by [***] of any default by Company of any provision

of this Agreement will not be deemed a waiver of any subsequent or other default.

23. Counterparts.

This Agreement may be executed in any number of counterparts, each of which will be deemed

to be an original, and all of which together will constitute one and the same agreement.

Each party acknowledges that an original signature or a copy thereof transmitted by facsimile

or by PDF will constitute an original signature for purposes of this Agreement.

24. Miscellaneous.

This Agreement includes all attached exhibits, all of which are herein incorporated by reference.

This Agreement contains the entire understanding of the parties with respect to the subject

matter hereof and supersedes all previous agreements and undertakings with respect thereto.

This Agreement may be modified only by written agreement signed by the parties. Unless otherwise

specifically set forth herein, no term hereunder serves to limit a party’s rights to

seek any applicable remedies available to it under law or equity. This Agreement will be

construed, governed, and interpreted in accordance with the laws of the state of Illinois,

excluding its conflicts of law provisions.

Signature

page follows

Feasibility Services Agreement CONFIDENTIAL 5

WITNESS WHEREOF, each of the parties has caused this Agreement to be executed by its authorized representative in its name and on

its behalf.

[***]

BullFrog

AI Holdings, Inc.

By:

Name:

Title:

Date:

Feasibility Services Agreement CONFIDENTIAL 6

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit

99.1

BullFrog

AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive

Disorder

Commercial

agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities

Agreement

utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug discovery and development program

GAITHERSBURG,

Md., March 30, 2026 — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”),

a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable

insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue (“Customer”),

to apply the Company’s proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive

disorder (MDD), accelerating the Customer’s drug discovery and clinical development program for this indication. The agreement

also provides exclusive access to a target candidate. The MDD market was valued at more than $8 billion in 2025 and expected to grow

at an average annual rate of nearly 5% to reach in excess of $11 billion by 2032, according to Stellar Market Research.

“This

agreement represents strong, high-quality validation of our proprietary capabilities from a leading industry partner, and we are confident

that this relationship will expand across other areas of the Customer’s research and development portfolio,” said BullFrog

AI Founder and CEO Vin Singh. “Our platform provides drug developers with an end-to-end analytical tool engineered to resolve multimodal

biological complexity at scale. Our bfLEAP®, bfPREP™, and bfARENASTM integrated platform leverages causal

network inference to provide drug developers a clearer path forward in the discovery and characterization of drug targets for complex

disease like MDD. We look forward to continuing to build on our successful record in identifying and prioritizing portfolios and expanding

our commercial partnerships.”

Additional

details of the agreement may be found in BullFrog AI’s Current Report on Form 8-K to be filed with the Securities and Exchange

Commission.

About

Major Depressive Disorder (MDD)

Major

depressive disorder (MDD) is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in

pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation

or agitation, sleep disturbances, or suicidal thoughts. One of the main causes of disability in the world, MDD has been ranked as the

third cause of the burden of disease worldwide in 2008 by World Health Organization, which has projected that this disease will rank

first by 2030.

About

BullFrog AI

BullFrog

AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading

research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex

biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit

BullFrog AI at: https://bullfrogai.com.

Safe

Harbor Statement

This

press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about

future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events

or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects

and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use

terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,”

“contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,”

“potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements,

you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new

technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog

Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business.

These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements

are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or

our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and

assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties

and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our

representatives might not occur.

Contact:

Investors:

CORE

ir@bullfrogai.com

Media:

CORE

pr@bullfrogai.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Mar. 27, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 27, 2026

Entity File Number

001-41600

Entity Registrant Name

BULLFROG

AI HOLDINGS, INC.

Entity Central Index Key

0001829247

Entity Tax Identification Number

84-4786155

Entity Incorporation, State or Country Code

Entity Address, Address Line One

325

Ellington Blvd

Entity Address, Address Line Two

Unit 317

Entity Address, City or Town

Gaithersburg

Entity Address, State or Province

Entity Address, Postal Zip Code

20878

City Area Code

(240)

Local Phone Number

658-6710

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Entity Information, Former Legal or Registered Name

Not

Applicable

Common Stock, par value $0.00001

Title of 12(b) Security

Common

Stock, par value $0.00001

Trading Symbol

BFRG

Security Exchange Name

NASDAQ

Tradeable Warrants

Title of 12(b) Security

Tradeable

Warrants

Trading Symbol

BFRGW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=BFRG_CommonStockParValue0.00001Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=BFRG_TradeableWarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: